# Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

> **NCT01288469** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 92 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Placebo (for alirocumab)
- **DRUG:** Atorvastatin
- **DRUG:** Placebo (for atorvastatin)

## Key facts

- **NCT ID:** NCT01288469
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2015-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01288469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01288469, "Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01288469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*